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Abstract 
Purpose: To prepare metformin HCl-loaded alginate (AL) and alginate-chitosan (AL-CS) beads for oral 
application and to evaluate their in vitro characteristics and in vivo activities.  
Methods: AL and AL-CS beads were prepared using ionotropic gelation. The beads were evaluated for 
particle size, surface morphology, drug encapsulation efficiency (EE) and in vitro drug release. The anti-
diabetic effects of the beads were evaluated in diabetic Sprague Dawley rats.  
Results: The mean particle sizes of AL and AL-CS beads in wet state ranged from 1714 ± 140 to 1850 
± 103 µm. The EE % of AL and AL-CS beads were 33.58 ± 1.56 and 24.11 ± 1.72, respectively, with 
sustained in vitro drug release of about 93 to 96 % within 8 days in phosphate buffer (PB). Optimized 
metformin HCl-loaded AL and AL-CS beads showed significant hypoglycaemic effects in diabetic rats 
over a prolonged period (about 12 h) after oral administration compared to the pure drug (p < 0.05).  
Conclusion: Metformin HCl-loaded AL and AL-CS beads for oral application may be useful in 
prolonging the hypoglycaemic effect of metformin. This is capable of increasing patients’ compliance to 
the medication.  
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Metformin hydrochloride is a biguanide derivative 
widely used for the treatment of Type 2 diabetes, 
and prescribed for about 120 million people 
worldwide [1-4]. Metformin is recommended by 
the European Association for the Study of 
Diabetes, and the American Diabetes 
Association as the first line therapy for Type 2 
diabetes [2,3]. Following oral administration, the 
drug is mainly absorbed from the upper small 
intestine, and has a relatively low bioavailability 
(absolute bioavailability of metformin is about 50 
to 60 %). Its biological half-life (t1/2) is in the 
range of 0.9 – 2.6 h. Therefore, repeated 
applications of high doses of the medicine are 
needed for effective treatment. As a result, 
patient compliance is reduced and/or the 
incidence of side effects such as diarrhoea, 
nausea, anorexia, vomiting, weight loss, and 
taste disturbance are increased [1,5]. Moreover, 
lactic acidosis, which is sometimes fatal, has 
occurred with biguanides [1]. Its incomplete 
absorption is improved by using convenient drug 
delivery systems such as bio-adhesive and 
gastro-retentive drug delivery systems [6,7]. In 
addition, the development of different types of 
formulation for metformin is necessary for 
reduction of dosing frequency of the drug and its 
gastrointestinal side effects [8]. 
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Sodium alginate, a salt of alginic acid, is a 
natural, polyanionic, non-toxic water-soluble 
copolymer of α-L-gluronic acid and β-D-
mannuronic acid residues. It is obtained from 
marine brown algae and has the ability to form a 
gel network in the presence of divalent cations 
such as calcium in aqueous media. Thus, 
alginate beads are successfully prepared by 
ionotropic gelation [9,10]. More effective beads 
for the controlled release of drugs can be 
prepared using the combination of chitosan and 
alginate. The poly-electrolyte complex is formed 
with the ionic interaction between the amino 
residues of chitosan and the carboxyl residues of 
alginate [10]. The addition of chitosan in the 
formulation alters the diffusion rate of the 
encapsulated drugs and causes the bulk 
modification of the alginate bead structure [11]. 
CS is a polysaccharide obtained by the de-
acetylation of chitin found in the exoskeleton of 
crustaceans (e.g. crab and shrimp) [12,13]. It has 
cationic character due to its primary amino 
groups and thus, shows muco-adhesive 
properties. AL beads and CS beads containing 
metformin HCl were prepared in previous studies 
[14,15]. In our study, besides metformin HCl-
loaded AL beads, we also prepared AL-CS 
beads containing metformin HCl using AL and 
CS combination. CS and AL are very useful in 
pharmaceutical applications and they are the 
most widely used hydrogels in the preparation of 
sustained release dosage forms [11,15,16]. 
 
The present study focuses on the development 
and in vitro characterization of metformin HCl-
loaded AL beads and AL-CS beads. It also 
focuses on in vivo evaluation of the 
hypoglycaemic activities of the bead formulations 







Metformin HCl was a generous gift from Sandoz 
Ilac Sanayi & Ticaret AS (Istanbul, Turkey). 
Sodium Alginate, STZ, nicotinamide and calcium 
chloride were obtained from Sigma-Aldrich 
(USA), and chitosan (Protosan UP CL 113) was 
purchased from FMC BioPolymer (Norway). All 
other chemicals and reagents were of analytical 
grade and used as they were received. 
 
Preparation of metformin HCl-loaded AL and 
AL-CS beads 
 
Metformin HCl-loaded AL and AL-CS beads were 
prepared by ionotropic gelation technique. 
Metformin HCl (100 mg) was dissolved in a 
sodium alginate aqueous solution (10 mL; 2 % 
w/v).  AL-drug solution (bubble-free) was 
dropped through a 26-gauge syringe needle into 
15 % (w/v) of calcium chloride solution on 
magnetic stirrer at 700 rpm for 15 min [17].The 
formed beads were further mixed in gelling 
medium at room temperature. After filtration, the 
beads were lyophilized for 24 h.  
 
In addition, the AL-CS beads were also prepared 
by ionotropic gelation technique. Metformin HCl 
(100 mg) was dissolved in a sodium alginate 
aqueous solution (10 mL; 2 % w/v). The solution 
was dropped through a 26-gauge syringe needle 
into 5 % (w/v) of calcium chloride solution (pH 
adjusted to 4.5) containing chitosan (0.5 %, w/v) 
on magnetic stirrer at 700 rpm for 15 min. The 
resultant AL-CS beads were further mixed in 
gelling medium at room temperature [18,19].  
After filtration, the beads were also lyophilized for 
24 h.  
 
Surface morphology and bead size 
 
The surface morphology and shape evaluation of 
the bead formulations were examined by 
Scanning Electron Microscope (SEM; Inspect 
S50, FEI, USA) (used for lyophilized beads) and 
digital photographs (used for wet beads). The 
size of wet beads was determined by Vernier 
callipers.  
 
Drug content of the beads 
 
Lyophilized beads (20 mg) in 20 mL of PB (pH 
6.8) in amber-coloured vials were sonicated for 
15 min and mixed at 750 rpm for 4 hr in the dark 
for complete extraction of metformin HCl. The 
dispersion was then centrifuged at 5000 rpm for 
15 min at 15 °C. The drug content of the 
supernatant of each sample was then measured 
using a validated UV method at 232 nm [20]. The 
experiment was performed in triplicate.  
 
In vitro release studies 
 
An incubation method was used for the 
investigation of metformin HCl release from 
beads in both media (PB, pH 6.8 and HCl, pH 
1.2). Lyophilized beads (20 mg) were suspended 
in 20 mL of PB (pH 6.8) or HCl (pH 1.2) in 
amber-colored vials and then immersed in a 
constant temperature (37 °C) water bath. At pre-
determined time intervals, samples (3 mL) were 
withdrawn from the release medium and 
replaced with the same volume of fresh buffer. 
All samples were centrifuged at 12500 rpm for 10 
min, and their drug contents were measured 
using a validated UV method at 232 nm (for PB 
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pH 6.8) and 209 nm (for HCl pH 1.2) [20]. The 




A Perkin-Elmer Spectrum One model FT-IR was 
used to record the IR spectra of AL, CS, 
metformin HCl, blank and metformin HCl-loaded 
beads prepared in KBr disks in the region of 
4000–400 cm-1. 
 
In vivo studies 
The animal experiments were conducted 
according to the ethical norms approved by the 
Ethics Committee of Ataturk University (May 31 
2013, No: 38). Fifty-nine male Sprague-Dawley 
rats (weighing 180 – 250 g) were obtained from 
the Experimental Animal Teaching and Research 
Center of the Experimental Animal Laboratory at 
Ataturk University. The rats were maintained on 
a normal diet and drinking water ad libitum at 24 
± 2 C and under a 12 h light/dark cycle. 
 
Analysis of fasting serum insulin levels 
 
The basal blood glucose levels of overnight-
fasted animals were determined using a 
glucometer (On.Call® Plus, Acon Lab, Inc, USA). 
Thereafter, diabetes was induced in the rats by 
administering a single intraperitoneal (i.p.) 
injection of freshly-prepared streptozotocin (STZ, 
40 mg/kg body weight (b.w.)) in cold citrate buffer 
(pH 4.5). After 15 min, the rats were given freshly 
prepared nicotinamide solution i.p. (120 mg/kg 
b.w) [21]. Diabetes was confirmed in the rats by 
measuring blood glucose levels on day 7 of the 
induction. Animals with fasting blood glucose 
higher than 126 mg/dL were considered to be 
diabetic. The blood samples of diabetic rats (n = 
8) collected from the tail veins were centrifuged 
(10,000 rpm, 10 min) and the supernatant was 
frozen until assayed for fasting serum insulin 
level using rat insulin enzyme immunoassay kit 
(SPI-BIO Bertin Pharma, France). The serum 
samples of control rats (healthy rats; n=8) were 
also analysed for fasting insulin level [21-23]. 
 
Evaluation of hypoglycaemic activity of 
beads in STZ-nicotinamide –induced diabetic 
rats 
 
The rats were divided into six different groups as 
follows: 
 
Group I: Control rats (healthy rats; n = 6) 
Group II: Diabetic control (n = 8) 
 
Group III: Diabetic rats treated with pure 
metformin HCl (100 mg/kg b.w) (n = 6) 
 
Group IV: Diabetic rats treated with blank beads 
(n = 8) 
 
Group V: Diabetic rats treated with metformin 
HCl-loaded AL-CS beads (equivalent to 
metformin HCl 100 mg/kg b.w.) (n = 9) 
 
Group VI: Diabetic rats treated with metformin 
HCl-loaded AL beads (equivalent to metformin 
HCl 100 mg/kg b.w.) (n=6) 
 
Type-2 diabetes was induced and controlled as 
described above. Diabetic rats were divided 
randomly into five different groups (Group II-
Group VI).The pure drug and the formulations of 
blank and metformin HCl-loaded beads were 
administered orally through a flexible plastic tube 
after an overnight fast. Fasting blood samples 
were collected through the tail vein of the rats at 
onset, then on the 2nd, 3rd, 4th, 6th, 8th and 12th hr 
after the treatment, and analysed for glucose 
using a glucometer. Changes in body weight for 
all experimental rats were monitored. The rats 
remained fasted throughout the experiment, but 




The experimental data are expressed as mean ± 
SD. Statistical evaluations were performed using 
Mann-Whitney U test (SPSS Statistics 20.0 
program; SPSS Inc, IL, USA). P < 0.05 was 




The SEM images and the digital photographs of 
metformin HCl-loaded AL and AL-CS beads (in 
dry and wet state, respectively) were shown in 
Figure 1. They were spherical in the wet state 
(Figure 1b and 1d). The values for particle size 
(in wet state) and EE % of all bead formulations 
are summarized in Table 1 while the in vitro drug 
release profiles were given in Figure 2. 
Regardless of the release medium, about 25 – 
40 % of the loaded metformin HCL was released 
from the beads during the initial burst release (60 
min). In addition, more than 93 % of the drug was 
released from both formulations in both media 
within 8 days (Figure 2). 
 
The FT-IR spectra of metformin HCl, AL, CS, and 
all bead formulations are presented in Figure 3 
and Figure 4. 
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Figure 1: Scanning Electron Microscope (SEM) images (a and c) and digital photographs (b and d), of metformin 
HCl-loaded-alginate and alginate-chitosan beads respectively 
 
Table 1: Particle size, encapsulation efficiency (EE) and drug loading (DL) of beads (mean ± SD) 
 
Formulation Mean particle size (m, 
n=36) 
EE (%, n=3) DL (%, n=3) 
Blank AL beads 1742±105 - - 
Blank AL-CS beads 1714±140 - - 
Metformin HCl loaded-AL 
beads 1850±103 33.58±1.56 1.98±0.08 
Metformin HCl 
loaded-AL-CS beads 1733±60 24.11±1.72 4.55±0.28 
AL = alginate; AL-CS = alginate-chitosan 
 
 
Figure 2: Release profiles of alginate and alginate-chitosan beads in HCl (pH 1.2) and phosphate buffer (pH 6.8). 
Values are mean ± SD (n = 3) 
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The FT-IR spectrum of AL polymer showed 
peaks at 3662.30 cm-1 due to O-H stretching, at 
2971.71 cm-1 because of aliphatic C-H stretching, 
at 1406.38 cm-1 due to symmetric and 
asymmetric carboxylate salt groups stretching, at 
1066.01 cm-1 related to C–O stretching, and at 
889.51 cm-1 due to C-C and C-C-H stretching 
(Figure 3) [24]. The spectrum of metformin HCl 
displayed peaks at 3367.79 cm-1 (N-H 
asymmetric stretching), at 3293.10 cm-1 and 
3149.27 cm-1 (N-H symmetric stretching), at 
1621.90 cm-1 (C=N stretching), at 1557.70 cm-1 
(N-H bending in plane), at 1472.57 cm-1,  at 
1447.01 cm-1 and  1417.93 cm-1 (C-H asymmetric 
bending; -CH3), at 1166.68 cm-1 and 1061.30 
cm-1 (C-N stretching), at 936.41 cm-1 and 735.82 
cm-1 (N-H wagging), at 632.29 cm-1 (NH2 rocking) 
and also at 550.02, 530.34 cm-1 (C-N-C bending) 
(Figure 3) [25,26]. Besides, the spectrum of CS 
presented peaks at 3232.49 cm-1 assigned to 
NH2 and O-H stretching, at 2879.55 cm-1 
because of C-H stretching (CH2), at 1616.78 cm-1 
attributed to C=O stretching, at 1146.85 cm-1 due 
to bridge-O stretching, at 1032.16 cm-1 and 
1060.13 cm-1assigned to C-O stretching, and at 
1373.42 cm-1 due to NHCO stretching (Figure 3) 
[27-29].  In the spectrum of metformin HCl-
loaded AL beads, the bands in 2987.66 cm-1, 
2896.93 cm-1, 1417.25 cm-1, 642.27 cm-1 related 
to the presence of metformin HCl were observed 
compared to the spectrum of blank AL beads 
(Figure 4). Besides, the spectrum of AL-CS 
beads containing drug showed that the intensity 
of the peaks attributed to vibrations in the 
spectrum of drug (3369.83 cm-1, 2988.71 cm-1, 
1626.76 cm-1, 1066.09 cm-1) increased and also 
bands were observed at 937.58 cm-1 and 732.86 
cm-1 (Figure 4). The FT-IR spectra of drug-loaded 
beads confirmed the presence of metformin HCl 
in both bead formulations. 
 
The fasting serum insulin levels of control rats 
and diabetic rats with fasting blood glucose level 
of higher than 126 mg/dL were found to be 0.66 
± 0.09 ng/mL and 0.51 ± 0.15 ng/mL, 
respectively. The reduction of fasting blood 
glucose level (as percentage of basal levels) 
after the administration of pure drug, and bead 
formulations versus time curves are given in 
Figure 5. The fasting blood glucose concen-
tration of Group II was higher than that of Group I 
(p < 0.05; Figure 5). Hypoglycaemic effect 
obtained for Groups V and VI were significantly 
different from that of Group III (p<0.05; except at 
3 and 4 hr for Group V, and 4 hr for Group VI). 
However, there was no a significant difference 
between the hypoglycaemic effects of both bead 




The results obtained in this study showed that 
the presence of chitosan in bead formulation had 
no significant effect on the size and drug content 
of the beads. Besides, the pH of the release 
medium had an effect on the drug release from 
AL beads, and a long-term hypoglycemic effect 
was observed in diabetic rats after oral 
administration of AL- and AL-CS- beads. The AL- 
and AL-CS-beads shrunk after freeze-drying, 
which is similar to the results reported by Zohar-
Perez et al [30]. There was a slight but 
insignificant difference between particle sizes of 
the blank and drug-loaded AL and AL-CS beads, 
indicating that the presence of chitosan and 
incorporation of metformin HCl into the beads did 
not influence the particle size. This observation is 
in a good agreement with the results of 
Rajendran and Basu, who reported that size of 
AL-beads was not significantly enhanced by the 
addition of chitosan to the formulation [11]. The 
low EE% values obtained for the beads might be 
due to the high solubility of metformin HCl in 
water resulting in drug leakage to the aqueous 
medium. Similar observation was also made by 
Ramteke et al [31]. These authors reported low 
encapsulation efficiency (about 25 %) for 
metformin HCl-loaded alginate beads prepared 
using CaCl2, an observation attributed to the high 
aqueous solubility of drug [31]. 
 
All drug release profiles displayed a biphasic 
release pattern characterized by an initial fast 
release (burst effect), followed by a slower 
release rate. The initial burst release is 
attributable to the high water solubility of the drug 
and its adsorption to the surface of the beads. In 
addition, although drug release from the AL-CS 
beads were very similar in both release media 
(28 vs. 27 % for pH 6.8 and pH 1.2 in the first 
hour), drug release from the AL beads seemed to 
be influenced slightly by the pH of the medium. 
The pH of the release medium affects the 
swelling of AL beads and the drug release from 
AL beads. In an acidic release medium, the 
reduction in the electrostatic repulsion due to the 
formation of COOH groups and intermolecular 
hydrogen bond results in the restriction of the 
relaxation of polymer chains and formation of 
more compact network and thereby reducing 
drug release. It was observed that the degree of 
swelling of AL beads increased with increase of 
pH of release medium, probably due to exchange 
of the Ca2+ ion with Na+. These results are in 
agreement with the results of previous studies 
[11,15]. 
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Figure 3:  FT-IR spectra of AL, metformin HCl and CS 
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Figure 4: FT-IR spectra of blank alginate beads, metformin HCl-loaded alginate beads, blank 
alginate-chitosan beads, metformin HCl-loaded alginate-chitosan beads 
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Figure 5: Blood glucose level (%) of rats (at 12 hr after treatments) in streptozotocin-nicotinamide-
induced diabetic rats after oral administration of metformin HCl-loaded alginate and alginate-chitosan 
beads and pure metformin HCl (Mean ± SD). Note: Group I: Control rats (n=6); Group II: Diabetic 
control (n=8); Group III: Diabetic rats treated with pure metformin HCl (n=6); Group IV: Diabetic rats 
treated with blank beads (n=8); Group V: Diabetic rats treated with metformin HCl-loaded alginate-
chitosan beads (n=9); Group VI: Diabetic rats treated with metformin HCl-loaded AL beads (n=6) 
 
Various approaches (chemicals, dietary 
manipulation, or surgery) are available in the 
literature for development of experimentally-
induced type 2 diabetes. For this purpose, we 
used STZ-nicotinamide. STZ taken up by 
pancreatic β-cells via GLUT2 (the glucose 
transporter) increases the production of free 
radicals and consequently causes impaired 
insulin secretion due to reduced insulin synthesis 
in β-cells and also the death of β-cells. On the 
other hand, nicotinamide prevents the STZ-
induced cytotoxicity. Tahara et al [22] reported 
that co-administration of nicotinamide (100 mg/kg 
b.w.) and streptozotocin (50 mg/kg b.w.) was 
successful in inducing mild diabetes in rats. 
Reduction in the fasting blood glucose level by 
the pure drug was obtained for 3 hr and the level 
restored after 3 hr. On the other hand, the fasting 
blood glucose levels of metformin HCl-loaded 
AL-CS and AL beads gradually declined and 
peaked in 6 hr and 4 hr, respectively, indicating 
that hypoglycaemic effect was extended by both 
bead formulations. Similar observations are 
reported in the literature [15,32]. Nayak et al [15] 
evaluated the hypoglycaemic effects of non-
floating and floating alginate beads containing 
metformin HCl on STZ-induced diabetic rats and 
found that a significant hypoglycaemic effect was 
obtained for floating beads 3 to 9 hr after bead 
administration. However, this effect was visible 
up to 5 hr after the administration of non-floating 
beads. Thus, floating beads were more useful for 
sustained hypoglycaemic effect, and a 25 % 
reduction in the blood glucose level was 
considered as significant hypoglycaemic effect. 
Similarly, following administration of metformin 
HCl-loaded fenugreek seed mucilage alginate 
muco-adhesive beads (equivalent to 100 mg/kg 
metformin HCl) to alloxan-induced diabetic rats, 
a significant hypoglycaemic effect was 
demonstrated up to 10 hr, and about 30 % 
reduction in blood glucose level was obtained 
during this period [32]. These results support our 
observation with regard to the prolonged 
hypoglycaemic effect obtained with metformin 




This study shows that HCl-loaded AL and AL-CS 
bead formulations may be useful in prolonging 
the hypoglycaemic effect of orally administered 
metformin. This is capable of increasing patient 
compliance with the medication. Further are, 
however, needed to explore the degree of side 
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